Celso Arango

A team of researchers from the United Kingdom has conducted a phase 2/3 clinical trial in people with a psychotic disorder to study the efficacy of interaction with a digital avatar in alleviating the discomfort generated by hearing voices. After analyzing it in 345 people, they conclude that it can reduce the frequency of occurrence at 16 and 28 weeks. The discomfort provoked is reduced at 16 weeks, but not at 28 weeks. The team publishes the results in the journal Nature Medicine.

The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.

The mental health of young people has deteriorated over the last two decades and is entering a dangerous phase, according to a new Commission by The Lancet Psychiatry. Several global factors are involved, including inaction on climate change, intergenerational inequality, and adversity linked to the COVID-19 pandemic. 

Physical activity is associated with significant reductions in depressive symptoms in children and adolescents, according to a systematic review and meta-analysis published in JAMA Pediatrics that included 21 studies with 2,400 participants. The largest decreases in these symptoms were found in those aged 13 years and older.